Filgrastim (G-CSF) Loaded Liposomes: Mathematical Modeling and Optimization of Encapsulation Efficiency and Particle Size

Overview

Journal Bioimpacts

Specialty Biomedical Engineering

Date 2017 Mar 8

PMID 28265535

Citations 3

Authors

Farhad Kiafar

Mohammad Reza Siahi Shadbad

Hadi Valizadeh

Affiliations

Soon will be listed here.

Abstract

Optimization of filgrastim (G-CSF) (granulocyte colony stimulating factor) liposomes formulation prepared by the method of film hydration was the aim of this research. To study the independent variables effects in the development of filgrastim (G-CSF) liposomes, method of factorial design was applied. The molar ratio of dipalmitoyl phophatidylcholine (DPPC) per cholesterol (Chol.) and hydration time were chosen as two independent factors. The dependent variables were encapsulation efficiency percent (EE %) and particle size (PS). Ultrafiltration method was applied for separation of un-encapsulated protein. RP-HPLC method was employed for analysis of G-CSF. Application of response surface methodology (RSM) in formulation of filgrastim liposomes and the obtained results for responses including particle size and EE % showed that the main effective independent variable was DPPC/Chol molar ratio. Different impacts of influencing parameters including interaction and individual effects were checked employing a mathematical method for obtaining desired liposomes. Optimum liposomal formulations were established using this method for enhancing their characteristics. Average percent errors (APEs) were 3.86% and 3.27% for predicting EE % and PS, respectively which reflect high model ability in this regard. It is concluded that observed and predicted values regarding PS and EE % were consistent and this model is efficient enough in prediction of the mentioned characteristics while preparing filgrastim (G-CSF) liposomes.

Citing Articles

2-AG-loaded and bone marrow-targeted PCL nanoparticles as nanoplatforms for hematopoietic cell line mobilization.

Kose S, Varan C, Onen S, Nemutlu E, Bilensoy E, Korkusuz P Stem Cell Res Ther. 2024; 15(1):341.

PMID: 39354544 PMC: 11446023. DOI: 10.1186/s13287-024-03902-1.

Physiologically Based Pharmacokinetic Modeling of Nanoparticle Biodistribution: A Review of Existing Models, Simulation Software, and Data Analysis Tools.

Kutumova E, Akberdin I, Kiselev I, Sharipov R, Egorova V, Syrocheva A Int J Mol Sci. 2022; 23(20).

PMID: 36293410 PMC: 9604366. DOI: 10.3390/ijms232012560.

Encapsulation of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor in liposomes prepared by thin film hydration and their transfer to mesenchymal stem cells and cord blood hematopoietic stem cells.

Lewicki S, Lesniak M, Sobolewska-Ruta A, Lewicka A, Grodzik M, Machaj E Arch Med Sci. 2022; 18(4):1051-1061.

PMID: 35832713 PMC: 9266718. DOI: 10.5114/aoms.2020.94527.

References

Ducat E, Brion M, Lecomte F, Evrard B, Piel G . The experimental design as practical approach to develop and optimize a formulation of peptide-loaded liposomes. AAPS PharmSciTech. 2010; 11(2):966-75. PMC: 2902352. DOI: 10.1208/s12249-010-9463-3. View

Kim T, Sakon M, Kawasaki T, Kambayashi J, Ohshiro T, Mori T . Studies on liposome-encapsulated heparin. Thromb Res. 1986; 43(6):603-12. DOI: 10.1016/0049-3848(86)90097-6. View

Herman A, Boone T, Lu H . Characterization, formulation, and stability of Neupogen (Filgrastim), a recombinant human granulocyte-colony stimulating factor. Pharm Biotechnol. 1996; 9:303-28. DOI: 10.1007/0-306-47452-2_7. View

Vanz A, Renard G, Palma M, Chies J, Dalmora S, Basso L . Human granulocyte colony stimulating factor (hG-CSF): cloning, overexpression, purification and characterization. Microb Cell Fact. 2008; 7:13. PMC: 2346455. DOI: 10.1186/1475-2859-7-13. View

Tan M, Choong P, Dass C . Recent developments in liposomes, microparticles and nanoparticles for protein and peptide drug delivery. Peptides. 2009; 31(1):184-93. DOI: 10.1016/j.peptides.2009.10.002. View

Samad A, Sultana Y, Aqil M . Liposomal drug delivery systems: an update review. Curr Drug Deliv. 2007; 4(4):297-305. DOI: 10.2174/156720107782151269. View

Kuderer N, Dale D, Crawford J, Lyman G . Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol. 2007; 25(21):3158-67. DOI: 10.1200/JCO.2006.08.8823. View

Yuba E, Kojima C, Harada A, Tana , Watarai S, Kono K . pH-Sensitive fusogenic polymer-modified liposomes as a carrier of antigenic proteins for activation of cellular immunity. Biomaterials. 2009; 31(5):943-51. DOI: 10.1016/j.biomaterials.2009.10.006. View

Niggemann B, Erdmann G, WELLHONER H . Liposome-entrapped [125I]anti-tetanus immunoglobulin G: evidence for entry into spinal cord neurons of the rat. Neurosci Lett. 1984; 51(2):231-4. DOI: 10.1016/0304-3940(84)90556-1. View

10.

Okabe M, Asano M, Kuga T, Komatsu Y, Yamasaki M, Yokoo Y . In vitro and in vivo hematopoietic effect of mutant human granulocyte colony-stimulating factor. Blood. 1990; 75(9):1788-93. View

11.

Balasubramanian S, Bruenn J, Straubinger R . Liposomes as formulation excipients for protein pharmaceuticals: a model protein study. Pharm Res. 2000; 17(3):344-50. DOI: 10.1023/a:1007561308498. View

12.

Montemurro F, Gallicchio M, Aglietta M . [Prevention and treatment of febrile neutropenia]. Tumori. 1997; 83(2 Suppl):S15-9. View

13.

Demetri G, Griffin J . Granulocyte colony-stimulating factor and its receptor. Blood. 1991; 78(11):2791-808. View

14.

Carbone C, Tomasello B, Ruozi B, Renis M, Puglisi G . Preparation and optimization of PIT solid lipid nanoparticles via statistical factorial design. Eur J Med Chem. 2012; 49:110-7. DOI: 10.1016/j.ejmech.2012.01.001. View

15.

Haeri A, Alinaghian B, Daeihamed M, Dadashzadeh S . Preparation and characterization of stable nanoliposomal formulation of fluoxetine as a potential adjuvant therapy for drug-resistant tumors. Iran J Pharm Res. 2014; 13(Suppl):3-14. PMC: 3977048. View

16.

Hermans K, van den Plas D, Everaert A, Weyenberg W, Ludwig A . Full factorial design, physicochemical characterisation and biological assessment of cyclosporine A loaded cationic nanoparticles. Eur J Pharm Biopharm. 2012; 82(1):27-35. DOI: 10.1016/j.ejpb.2012.05.003. View

17.

Derakhshandeh K, Erfan M, Dadashzadeh S . Encapsulation of 9-nitrocamptothecin, a novel anticancer drug, in biodegradable nanoparticles: factorial design, characterization and release kinetics. Eur J Pharm Biopharm. 2006; 66(1):34-41. DOI: 10.1016/j.ejpb.2006.09.004. View

18.

Duconge J, Rodriguez-Vera L, Valenzuela C, Alvarez D, Ramirez O, de la Luz-Hernandez K . Pharmacokinetic comparison of two recombinant human granulocyte colony-stimulating factor after subcutaneous administration in rabbits. Eur J Pharm Biopharm. 2005; 61(3):142-8. DOI: 10.1016/j.ejpb.2005.06.003. View

19.

Hao J, Wang F, Wang X, Zhang D, Bi Y, Gao Y . Development and optimization of baicalin-loaded solid lipid nanoparticles prepared by coacervation method using central composite design. Eur J Pharm Sci. 2012; 47(2):497-505. DOI: 10.1016/j.ejps.2012.07.006. View

20.

Choi S, Park T . G-CSF loaded biodegradable PLGA nanoparticles prepared by a single oil-in-water emulsion method. Int J Pharm. 2006; 311(1-2):223-8. DOI: 10.1016/j.ijpharm.2005.12.023. View